EMA Recommends Extension of Therapeutic Indications for Cabozantinib
New indication concerns the treatment of patients with differentiated thyroid carcinoma refractory or not eligible to radioactive iodine
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Increased Risk of Cancer in Early Life Among Individuals with Autism Spectrum Disorders
Increased cancer risk among individuals with autism is likely attributable to co-occurring intellectual disability and/or birth defects
FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Evidence for efficacy is based on the results from the ZUMA-7 study
Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with Newly Diagnosed IDH1-Mutated AML
Findings from a phase III, AGILE study in patients with newly diagnosed IDH1-mutated acute myeloid leukaemia ineligible for induction chemotherapy
Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Findings from final prespecified overall survival analysis and an update on radiographic progression-free survival in the ARCHES study
EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel
It is intended for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies
First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer Types
Patients with mental illness significantly more likely to experience premature mortality
A Systematic Analysis of the Global Burden of Disease from 2010 to 2019 Suggests Increase in New Cancer Cases, Cancer Deaths and Disability-Adjusted Life Years
The estimates varied substantially by Sociodemographic Index quintile, highlighting global inequities in cancer burden
Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC
Findings from a multi-basket MyPathway study
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
It also approved gallium Ga 68 gozetotide, a radioactive diagnostic agent for PET of PSMA-positive lesions
EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin
New indication concerns the treatment of adult patients with previously untreated diffuse large B-cell lymphoma
FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
Efficacy was evaluated using real-world data from the EPIK-P1 study